Athena Countouriotis is CEO & President at Turning Point Therapeutics, Inc. (TPTX). They have made 7 open-market trades across 2 companies since 2019, most recently 2026-06-02.
CIK 0001571469
5 open-market purchases totalling $1.2M since 2019, against 2 sales. Across 5 scored buys the stock is up 43.3% at ninety days, and 34.2 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 40% | 60% | 100% |
| Avg Move | -2.9% | +5.9% | +43.3% |
| Alpha | -2.8% | +7.4% | +34.2% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| TPTX | SELL | 2022-02-09 | 2022-02-11 | $36.30 | $216K | -8.3% | -28.0% | -14.6% |
| TPTX | SELL | 2021-02-09 | 2021-02-11 | $137.55 | $15.6M | -11.0% | -17.3% | -50.3% |
| TPTX | BUY | 2020-05-21 | 2020-05-26 | $60.00 | $250K | -3.1% | +3.2% | +11.6% |
| PASG | BUY | 2020-03-24 | 2020-03-25 | $14.98 | $150K | +6.8% | +26.2% | +141.4% |
| PASG | BUY | 2020-03-03 | 2020-03-03 | $18.00 | $160K | -23.6% | -25.3% | +7.9% |
| TPTX | BUY | 2019-09-10 | 2019-09-11 | $45.00 | $450K | -14.4% | -19.6% | +16.5% |
| TPTX | BUY | 2019-04-22 | 2019-04-24 | $18.00 | $216K | +19.8% | +45.3% | +38.9% |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.